Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $20.40

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.40.

Several brokerages have recently commented on BCRX. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 29th. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $13.00 to $11.00 in a research note on Thursday, September 10th. Wedbush reduced their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.76 on Tuesday. The stock has a market capitalization of $2.24 billion, a PE ratio of -5.84 and a beta of 0.57. The firm’s fifty day moving average price is $9.41 and its 200 day moving average price is $9.25. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 EPS. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $238,930,000. Jupiter Topco LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $95,268,000. Bank of America Corp DE acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $48,013,000. Perceptive Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the period. Finally, RFG Advisory LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $27,329,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.